ReviewImmunologic research2016
Roles of A20 in autoimmune diseases.
Review in Immunologic research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Tumor necrosis factor alpha-induced protein 3: A key biomarker for response to ursodeoxycholic acid in primary biliary cholangitis.World journal of hepatology · 2025Article
- Seronegative Sicca Syndrome: Diagnostic Considerations and Management Strategies.Life (Basel, Switzerland) · 2025Review
- Beyond survival to domination:Frontiers in microbiology · 2025Review
- Research Progress of A20 in Acute Leukemia: A20 in Acute Leukemia.Galen medical journal · 2025Review
- Case Report: Sequential treatment with rituximab and belimumab in a pediatric patient of type 1 diabetes mellitus complicated with systemic lupus erythematosus.Frontiers in pediatrics · 2025Article
- Genetic Mutations Associated With TNFAIP3 (A20) Haploinsufficiency and Their Impact on Inflammatory Diseases.International journal of molecular sciences · 2024Review
- A20 in Kidney Transplantation and Autoimmunity.International journal of molecular sciences · 2024Review
- Identification of potential drug targets for allergic diseases from a genetic perspective: A mendelian randomization study.Clinical and translational allergy · 2024Article
- Attenuation of HOIL-1L ligase activity promotes systemic autoimmune disorders by augmenting linear ubiquitin signaling.JCI insight · 2024Article
- Identification of drug targets for Sjögren's syndrome: multi-omics Mendelian randomization and colocalization analyses.Frontiers in immunology · 2024Article
- Mast cell tolerance in the skin microenvironment to commensal bacteria is controlled by fibroblasts.Cell reports · 2023Article
- Vasculitis and vasculopathy associated with inborn errors of immunity: an overview.Frontiers in pediatrics · 2023Review
- Genome Editing Using CRISPR-Cas9 and Autoimmune Diseases: A Comprehensive Review.International journal of molecular sciences · 2022Review
- TNFAIP3 alleviates pain in lumbar disc herniation rats by inhibiting the NF-κB pathway.Annals of translational medicine · 2022Article
- Characterization of Cellular Heterogeneity and an Immune Subpopulation of Human Megakaryocytes.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- Overexpression of the ubiquitin-editing enzyme A20 in the brain lesions of Multiple Sclerosis patients: moving from systemic to central nervous system inflammation.Brain pathology (Zurich, Switzerland) · 2021Article
- Haploinsufficiency of A20 Due to Novel Mutations in TNFAIP3.Journal of clinical immunology · 2020Article
- A20 Restores Impaired Intestinal Permeability and Inhibits Th2 Response in Mice with Colitis.Digestive diseases and sciences · 2020Article
- Decreased A20 expression on circulating CD56Clinical and experimental immunology · 2019Article
- Herbs-partitioned moxibustion alleviates aberrant intestinal epithelial cell apoptosis by upregulating A20 expression in a mouse model of Crohn's disease.World journal of gastroenterology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A20 (TNFAIP3), known to inhibit NF-κB function by deubiquitinating-specific NF-κB signaling molecules, has been found in many cell types of the immune system. Recent findings suggest that A20 is essential for the development and functional performance of dendritic cell, B cell, T cell and macrophage. A number of studies further demonstrate that these cells are crucial in the pathogenesis of autoimmune diseases, such as type 1 diabetes, systemic lupus erythematosus, inflammatory bowel disease, ankylosing arthritis, Sjögren's syndrome and rheumatoid arthritis. In this article, we focus on the recent advances on the roles of A20 in autoimmune diseases and discuss the therapeutic significance of these new findings.
Indexed as
Identifiers
26135958What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.